Signal Advisors Wealth LLC Purchases New Shares in CVS Health Corporation $CVS

Signal Advisors Wealth LLC purchased a new stake in CVS Health Corporation (NYSE:CVS) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 3,296 shares of the pharmacy operator’s stock, valued at approximately $227,000.

A number of other institutional investors have also recently added to or reduced their stakes in CVS. Goldman Sachs Group Inc. boosted its stake in CVS Health by 87.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 9,927,650 shares of the pharmacy operator’s stock worth $672,598,000 after purchasing an additional 4,632,530 shares during the last quarter. Dodge & Cox boosted its stake in CVS Health by 4.8% during the 1st quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock worth $4,976,856,000 after purchasing an additional 3,353,223 shares during the last quarter. Nuveen LLC acquired a new stake in CVS Health during the 1st quarter worth $204,421,000. Assenagon Asset Management S.A. boosted its stake in CVS Health by 310.8% during the 1st quarter. Assenagon Asset Management S.A. now owns 3,523,824 shares of the pharmacy operator’s stock worth $238,739,000 after purchasing an additional 2,666,029 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in CVS Health by 13.2% during the 1st quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator’s stock worth $1,383,039,000 after purchasing an additional 2,375,764 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insider Activity at CVS Health

In other news, Director Anne A. Finucane sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total transaction of $532,650.00. Following the completion of the sale, the director owned 22,156 shares in the company, valued at $1,573,519.12. This represents a 25.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.22% of the stock is owned by company insiders.

CVS Health Stock Performance

Shares of CVS Health stock opened at $74.95 on Friday. CVS Health Corporation has a one year low of $43.56 and a one year high of $76.24. The company has a market cap of $95.06 billion, a PE ratio of 20.94, a P/E/G ratio of 0.83 and a beta of 0.62. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 0.80. The business has a 50-day simple moving average of $67.91 and a 200-day simple moving average of $66.63.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.35. The business had revenue of $98.92 billion during the quarter, compared to the consensus estimate of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The business’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.83 earnings per share. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts forecast that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd will be paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.5%. The ex-dividend date is Thursday, October 23rd. CVS Health’s dividend payout ratio is 74.30%.

Analysts Set New Price Targets

Several brokerages have issued reports on CVS. Jefferies Financial Group lifted their target price on shares of CVS Health from $74.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, June 30th. Barclays lifted their target price on shares of CVS Health from $80.00 to $87.00 and gave the stock an “overweight” rating in a research note on Thursday, September 4th. Cantor Fitzgerald reiterated an “overweight” rating and set a $78.00 price target on shares of CVS Health in a report on Tuesday, August 26th. Zacks Research lowered CVS Health from a “strong-buy” rating to a “hold” rating in a report on Monday, September 8th. Finally, UBS Group upgraded CVS Health from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $67.00 to $79.00 in a report on Monday, August 18th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $77.89.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.